Investors were greeted with an intriguing rumor early Tuesday
morning, as the Wall Street Journal and other financial news sources
were reporting that Actavis (NYSE: ACT ) and Forest Labs (NYSE: FRX ) were closing in on a deal. It didn't take long for this to play out, as Actavis announced the deal before the market opened.
This is a bold move for Actavis, as Forest Labs substantially expands
its therapeutic end-markets, its addressable health care markets, and
its balance sheet. There are definitely rich opportunities for
operational and financial synergy here, but successful execution on this
premium deal is an absolute must.
Read more:
Actavis PLC Buys Pricey Lumber with Forest Labs
No comments:
Post a Comment